How to Determine Product Classification for Overseas Registration of Disinfection and Sterilization Equipment

Product classification for disinfection and sterilization equipment in overseas registration must be determined on a country-by-country basis. It cannot be inferred solely from the domestic NMPA classification. Classification directly determines the registration pathway, technical documentation requirements, and review intensity. Manufacturers should first confirm whether the device falls within the target country's regulatory scope, then evaluate the risk class according to local rules, determine the applicable registration pathway, assess reuse of existing evidence, and meet localisation and post-market maintenance requirements. Misclassification can lead to incorrect registration pathways, mismatched technical files, prolonged correction cycles, and difficulties with change control or certificate renewal.

Published: 2026-08-26 19:11 | Updated: 2026-08-26 19:11

Executive Summary

In overseas registration of disinfection and sterilization equipment, product classification is the primary factor that determines the registration pathway, technical documentation requirements, and depth of regulatory review. Manufacturers cannot rely on the domestic Class II or Class III medical device classification alone. They should confirm the regulatory scope, risk class, and classification rules for each target country. The determination process includes: (1) confirming whether the device is a medical device or is otherwise regulated; (2) evaluating the risk class under the target country's rules; (3) assessing whether existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation can be reused; and (4) conducting a gap analysis for intended use, sterilization parameters, biocompatibility, performance verification, risk management, clinical evaluation, labelling, local agents, and post-market maintenance requirements. Common risks include incorrect classification leading to wrong registration pathways, mismatched technical files, prolonged correction cycles, and difficulties in change control or certificate renewal due to neglect of local agent responsibilities. Manufacturers should complete the target-country classification research before project initiation, build a reusable core technical file package, and confirm classification differences with regulatory consultants to reduce duplication and correction risks.

Applicable Scenarios and Core Issues

Disinfection and sterilization equipment is widely used in healthcare facilities, pharmaceutical companies, laboratories, and public health settings. Typical products include autoclaves, ethylene oxide sterilizers, low-temperature plasma sterilizers, hydrogen peroxide gas plasma sterilizers, dry heat sterilizers, ultraviolet disinfection equipment, washer-disinfectors, and endoscope washer-disinfectors. In overseas registration, the product classification directly determines the registration pathway, technical documentation requirements, review intensity, and post-market obligations.

A core issue is that the same sterilizer classified as Class II or III in China may be assigned a different risk class in Southeast Asia, the Middle East, Latin America, or GHWP member countries, and in some cases may even be treated as a non-medical or industrial device. For example, a large steam sterilizer intended for medical device sterilization may be regulated as Class IIb or Class B in one country, while another country may require clinical evaluation under a higher risk class.

Another common issue is unclear classification rationale. Sterilization equipment can act through physical means (heat, pressure, radiation, filtration) or chemical means (ethylene oxide, hydrogen peroxide, formaldehyde steam), and may come into contact with human tissue or process implants, blood, and other materials. Intended use, contact time, contact site, sterilization load, and sterilization effectiveness validation standards all affect classification. Manufacturers should first define the intended use and key design characteristics, then look up official classification rules, guidance, and consultation conclusions for each country.

Typical scenarios include: first entry into a foreign market; having CE or FDA approval but wishing to enter GHWP member countries; multi-country registration of the same product; localisation of existing technical files; and re-evaluation of classification after design changes. Accurate classification is essential to avoid selecting the wrong registration pathway, submitting incomplete technical files, and incurring additional testing and review costs.

Registration Classification Logic

The classification judgment should follow the logical sequence: regulatory scope – risk class – registration pathway – applicant entity – documentation reuse – localisation requirements.

Step 1: Confirm whether the product is a medical device in the target country

Most countries consider devices used to sterilize medical instruments, surgical instruments, or implants as medical devices. However, some countries exclude sterilizers used only in food, pharmaceutical, or laboratory settings from medical device regulation. Manufacturers should check the target country's medical device definition, classification rules, and exemption lists, and apply for a formal classification determination when necessary.

Step 2: Determine the risk class under target-country rules

The FDA determines class under 21 CFR 862–892, with common sterilization devices falling into Class I, II, or III. Under the EU MDR, these devices are typically Class IIa or IIb. Southeast Asian countries generally follow an ASEAN classification framework or their own classification tables. Middle Eastern and Latin American countries may reference GHTF or have their own rules. Manufacturers should assess the sterilization method, contact nature, use environment, and patient impact.

Step 3: Clarify the registration pathway and applicant entity

Different risk classes correspond to different pathways. Low-risk products may require self-declaration or simplified registration, while high-risk products require full technical files and review or inspection. Most countries require the overseas manufacturer to appoint a local agent or authorised representative responsible for submitting the application, receiving regulatory communications, and acting as the ongoing point of contact. Manufacturers should plan the local agent arrangement in advance and clearly define the agent's authority and responsibilities.

Step 4: Assess reuse of existing documentation

If the manufacturer holds an NMPA registration certificate, CE technical files, FDA 510(k) or PMA, an ISO 13485 certificate, or MDSAP certification, these should be compared item by item against the target country's technical file format and language requirements. Key performance parameters, sterilization cycle validation, physicochemical properties, biocompatibility, electrical safety, and electromagnetic compatibility data are often reusable, but the target country may require local testing or re-validation.

Step 5: Address localisation and post-market maintenance requirements

Labels and instructions for use must be translated into the official language of the target country and comply with local units, warnings, and symbols. The target country may also require sterilization validation data, biological indicator results, residual toxicity analysis, and clinical evaluation or evidence. Manufacturers must comply with post-market surveillance, adverse event reporting, annual updates, and certificate renewal rules. For multi-country registration, a unified technical file base should be established and adapted locally to reduce duplication and correction risks.

Documentation and Evidence

Classification decisions must be supported by technical documentation. The manufacturer should prepare a product description, intended use, principle of operation, sterilization method, sterilization dose or parameters, applicable sterilization loads, and compatibility with patient-contact devices. For different target countries, risk management reports, performance verification reports, biocompatibility test reports, software lifecycle documentation, and clinical evaluation or evidence may also be required.

Sterilization validation documents are particularly important. EO sterilizers require reports on cycle development, biological indicator challenges, and residue testing for ethylene oxide and ethylene chlorohydrin. Steam sterilizers require data on temperature distribution, heat penetration, biological indicators, and physical parameter validation. Low-temperature plasma and hydrogen peroxide sterilizers require material compatibility and hazardous residue analysis. These data demonstrate effectiveness and safety and are also key inputs for risk classification.

Quality management system documentation proving compliance with ISO 13485 or MDSAP is also required. Reviewers will scrutinise design input/output, risk management, supplier control, production processes, and post-market surveillance records. If the manufacturer holds CE or FDA approval, all technical files and reports should be retained as a basis for reuse.

The following evidence is critical for classification and registration file preparation:

• Product name, model, intended use, environment of use, and operator instructions.
• Sterilization principle, sterilant composition, and mechanism of action.
• Sterilization cycle parameters, loading methods, and biological/chemical indicator validation reports.
• Body contact mode, contact time, contact materials, and potential toxicity assessment.
• Declaration of conformity, applicable test standards, and test laboratory qualification.
• Risk management report and demonstration that residual risks are acceptable.
• Clinical evaluation or clinical evidence, particularly for implants or high-risk devices.
• Multi-language versions of labels, instructions, warnings, and training materials.

Additionally, the target country may require the original country registration certificate, free sale certificate, or GMP certificate. If the product contains software or data interfaces, such as sterilisation data recording systems or remote monitoring modules, software safety class, cybersecurity, and usability engineering evidence must be submitted. All documents should be version-controlled and dated to ensure consistency across submissions.

Common Mistakes

Manufacturers often make the following errors in classification determinations:

• Directly mapping the domestic Class II/III classification to overseas classes without considering country-specific rules.
• Ignoring the target country's definition of medical device sterilizer, and mistakenly registering an industrial sterilizer as a medical device, or vice versa.
• Evaluating only the sterilizer itself while overlooking how the sterilized item and contact mode affect the risk class.
• Relying on internal judgment without formally requesting a classification determination from the regulator, leading to an incorrect pathway.
• Reusing CE or FDA documents without a gap analysis, ignoring specific local requirements for sterilization validation, residues, and clinical data.
• Underestimating the role of the local agent and failing to clarify responsibilities for certificate control, change submissions, and renewal.
• Neglecting post-market obligations and failing to establish a local adverse event reporting and vigilance system.
• In multi-country registrations, failing to maintain a unified core technical file, causing inconsistent submissions and increased correction risk.

These mistakes can lead to rejected applications, prolonged review or correction cycles, higher registration costs, and even fines or product recalls due to incongruence between sterilization dose descriptions and local requirements. Early classification research and regulatory consulting can systematically avoid these issues.

Preparedness Checklist for Companies

To complete overseas registration successfully, manufacturers should work through the following checklist:

• Identify the regulatory authority, legal basis, and product classification rules for each target country.
• Compile the product technical specification, intended use, sterilization principle, and list of items to be sterilized.
• Complete or update the risk management report, identifying risks associated with the sterilizer and the sterilant.
• Prepare sterilization validation data, including cycle development, performance qualification, and biological indicator testing.
• Assess the need for biocompatibility testing or chemical analysis of materials.
• Verify which existing certificates and reports (CE, FDA, NMPA, MDSAP) can be reused.
• Confirm whether the target country requires local testing, local clinical evaluation, or clinical data.
• Sign a local agent or authorized representative agreement, specifying responsibilities and fees.
• Create multi-language labels and instructions, with translation and regulatory review completed.
• Establish a post-market surveillance plan, including adverse event reporting, annual reviews, and update processes.
• Develop a multi-country registration timeline and budget, prioritized by risk class and market importance.

Companies should integrate this checklist into project management forms and confirm each item with a regulatory affairs specialist or external consultant. All classification rationale and test reports must be retained to respond to regulator queries.

AIMEILI Perspective

In our long-term practice assisting manufacturers with multi-country registration of disinfection and sterilization equipment, we find that the most frequent misconception is equating sterilization equipment with sterilization effectiveness. Companies tend to focus on technical parameters while ignoring how the target country defines the sterilized object and clinical contact risk. For example, a small steam sterilizer used for rapid sterilization of surgical instruments may be classified higher than a laboratory sterilizer due to higher patient-contact risk. If a company submits based on domestic classification or past experience, the registration pathway can be wrong.

We recommend that companies spend two to three weeks on a target-country classification study before project initiation. This is not just a matter of looking up a classification table; it also involves confirming with the local regulator or authorized representative whether the intended use description is acceptable. Prepare an English version of the product description and use scenarios, request classification opinions from the agent, and submit a formal classification determination if needed. The investment at this stage is small but can prevent costly rework of technical files later.

Regarding document reuse, core physicochemical properties, electrical safety, and sterilization cycle validation reports are usually transferable across countries. However, biocompatibility, clinical evaluation, and residual toxicity data may need to be reassessed according to local requirements. EO sterilizers in particular require localized analysis because EO residue limits and detection methods can differ by country. Labels and instructions for use should never be simply translated; each country has specific rules on warnings, icons, sterilization parameter presentation, and lists of applicable devices.

Local agents and certificate control are extremely important. Many countries list the agent as the certificate holder or contact point. If the agent changes or provides poor service, change control, renewal, and adverse event reporting can be delayed. Companies should define in the contract: response time, custody of original certificates, authority to submit changes, and renewal reminders. Also ensure that the manufacturer's name, address, and QMS information appear accurately on the registration certificate to avoid customs clearance issues.

For companies planning to enter several GHWP member countries or other overseas markets, we recommend building a core sterilization equipment technical file package that includes product description, risk management, sterilization validation, performance data, and QMS documentation. From this foundation, adapt classification explanations, clinical evaluations, and label content to each country's requirements. This approach significantly reduces the time and cost of duplicating documents and corrections while ensuring consistency and traceability across submissions.

Frequently Asked Questions

Do all disinfection and sterilization devices have to be registered as medical devices?

No. If a device is used only for sterilizing food, pharmaceutical production, or non-medical laboratory items, some countries classify it as industrial or laboratory equipment and outside medical device regulation. However, if the device is used in a healthcare facility to sterilize surgical instruments, implants, or patient-contact devices, it is generally treated as a medical device. The determination is based on the target country's medical device definition and the stated intended use. Manufacturers should provide a clear intended-use statement and, if necessary, obtain confirmation from the regulator.

If I already have a CE Class IIb certificate, can I register directly as Class IIb in Southeast Asia?

No, you cannot directly substitute the CE class. Most Southeast Asian countries use their own classification framework or reference the ASEAN classification guidance, which may use Class B or Class C designations. The CE class is only a reference and does not replace the target country's classification. Manufacturers must evaluate the sterilizer, its sterilization method, and contact risk under the local rules and prepare matching technical files. In practice, a CE Class IIb steam sterilizer may be classified as Class C or Class IIb in Thailand or the Philippines, but the submission must still meet locally required specific data.

Can sterilization validation reports be shared across multiple country registrations?

The core content of sterilization validation reports, such as cycle development, biological indicator tests, and physical parameter validation, can be shared. However, different countries may require validation methods that follow different standard versions, or require reference to international standards such as ISO 11135, ISO 11138, or ISO 14937. The target country may also impose additional requirements on the qualification of testing facilities and the language of reports. Manufacturers should retain complete raw data and issue English or local-language versions as required. For EO residue testing, check whether residue limits are consistent across countries and perform additional testing when necessary.

Disclaimer: This article is compiled from AIMEILI's regulatory practice database, international medical device registration knowledge base, and publicly available regulatory information. Specific projects should be verified against the target country's latest regulatory requirements and the actual product documentation.